Stock-Based Compensation Plans (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Apr. 20, 2007
Stock-Based Compensation Plans (Textual) [Abstract]
Approval date of 2007 Stock Award and Incentive Plan					Apr. 20, 2007
New shares issued under the plan					2,500,000
Issued shares transferred from 2000 Stock Option Plan					374,264
Issued shares transferred from Directors Stock Plan					401,070
Issuance of aggregate shares					3,275,334
Shares available for future grants under the plans	360,468		360,468
Compensation expense related to research and development	$ 20,000		$ 50,000
Compensation expense related to general and administrative expenses	60,000		180,000
Total compensation expense for share-based payments awards	80,000		230,000
Total unrecognized estimated compensation expense related to non-vested stock options granted	400,000		400,000
Stock plan expected to be recognized over a weighted-average approximate period			2 years
Options exercised	0	0	0	0
Tax Benefit	0		0
Total options granted			2,696,750
Number of options granted to new members			100,000
Number of options granted to each member as part of annual compensation			40,000
Number of options to Michael Garone, Interim CEO, CFO and VP			45,000
Number of options to M. Gary Riley, Vice president of Non clinical Development and Applied Biology			30,000
Number of options to other employees			106,750
Number of option to Alan Rubino president and CEO			2,000,000
Number of option to Timothy Rothwell, Chairman of the Board of Directors			175,000
Number of new members of Board of Directors			$ 2